CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $1.04B, above the global median of $548.88M
- PositionDebt-to-equity is 5.67×, higher than 95% of its Medical Devices peers (median 0.22×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.09BUSDvs all stocks (USD)
Revenue (TTM)
1.04BUSDvs all stocks (USD)
Profit Margin
-6.08%vs Medical Devices peers
Beta
1.56xvs all stocks
52-Week Change
35.03%vs all stocks
Market Capitalization
1.09BUSDvs all stocks (USD)
Enterprise Value
1.38BUSDvs all stocks (USD)
Forward P/E
96.36xvs Medical Devices peers
Price to Sales (TTM)
1.08xvs Medical Devices peers
Price to Book (MRQ)
8.62xvs Medical Devices peers
Enterprise to Revenue
1.32xvs Medical Devices peers
Enterprise to EBITDA
-55.01xvs Medical Devices peers
Gross Margin
56.87%vs Medical Devices peers
Profit Margin
-6.08%vs Medical Devices peers
Operating Margin
-5.42%vs Medical Devices peers
Return on Assets (TTM)
-2.65%vs Medical Devices peers
Return on Equity (TTM)
-48.03%vs Medical Devices peers
Revenue (TTM)
1.04BUSDvs all stocks (USD)
Revenue per Share (TTM)
15.25USDUpdated Sep 28, 2026Quarterly Revenue Growth
5.80%vs Medical Devices peers
Gross Profit (TTM)
583.32MUSDvs all stocks (USD)
EBITDA (TTM)
-25.03MUSDvs all stocks (USD)
Net Income (TTM)
-63.31MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-5.52MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-43.95MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
1.01BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
468.72MUSDFY2025 · Dec 31, 2025Gross Profit
546.01MUSDFY2025 · Dec 31, 2025Operating Income
-167.31MUSDvs all stocks (USD)
Pre-tax Income
-200.27MUSDFY2025 · Dec 31, 2025Income Tax Expense
4.44MUSDFY2025 · Dec 31, 2025Net Income
-204.71MUSDFY2025 · Dec 31, 2025EBIT
-194.22MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-156.61MUSDFY2025 · Dec 31, 2025Research & Development
268.33MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
444.99MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
9.09MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
6.05MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.04USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.04USDFY2025 · Dec 31, 2025Basic Shares Outstanding
67.28MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
67.28MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-204.71MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-19.81MUSDFY2025 · Dec 31, 2025Free Cash Flow
-39.76MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
90.63MUSDFY2025 · Dec 31, 2025Income Tax Paid
5.06MUSDFY2025 · Dec 31, 2025Interest Paid
5.05MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-204.71MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
17.67MUSDFY2025 · Dec 31, 2025Stock-based Compensation
92.38MUSDFY2025 · Dec 31, 2025Other Non-cash Items
88.14MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-56.81MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.23MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
41.30MUSDFY2025 · Dec 31, 2025Capital Expenditures
-19.95MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-78.59MUSDFY2025 · Dec 31, 2025Purchase of Investments
-85.66MUSDFY2025 · Dec 31, 2025Sale of Investments
257.07MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
151.46MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-40.76MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-40.76MUSDFY2025 · Dec 31, 2025Shares Outstanding
69.54MSharesUpdated Sep 28, 2026Float Shares
63.76MSharesUpdated Sep 28, 2026Shares Short
12.47MSharesUpdated Sep 28, 2026Short Ratio
8.11daysvs all stocks
Short % of Shares Outstanding
24.01%vs all stocks
% Held by Insiders
1.17%vs all stocks
% Held by Institutions
115.72%vs all stocks
Total Cash (MRQ)
456.00MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.55USDUpdated Sep 28, 2026Total Debt (MRQ)
739.25MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
5.67xvs Medical Devices peers
Current Ratio (MRQ)
3.18xvs Medical Devices peers
Book Value per Share (MRQ)
1.88USDUpdated Sep 28, 2026Total Assets
881.11MUSDvs all stocks (USD)
Total Current Assets
618.14MUSDFY2025 · Dec 31, 2025Total Liabilities
725.94MUSDFY2025 · Dec 31, 2025Total Non-current Assets
262.97MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
483.22MUSDFY2025 · Dec 31, 2025Total Current Liabilities
242.72MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
90.63MUSDFY2025 · Dec 31, 2025Other Short-term Investments
202.03MUSDFY2025 · Dec 31, 2025Accounts Receivable
165.49MUSDFY2025 · Dec 31, 2025Inventory
128.77MUSDFY2025 · Dec 31, 2025Accounts Payable
47.07MUSDFY2025 · Dec 31, 2025Short-term Debt
19.47MUSDFY2025 · Dec 31, 2025Deferred Revenue
9.53MUSDFY2025 · Dec 31, 2025Other Current Liabilities
75.24MUSDFY2025 · Dec 31, 2025Long-term Debt
425.00MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
49.74MUSDFY2025 · Dec 31, 2025Common Stock (Book)
68.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.25BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
155.17MUSDvs all stocks (USD)
52-Week Low
11.46USDUpdated Sep 28, 202652-Week High
29.65USDUpdated Sep 28, 202652-Week Change
35.03%vs all stocks
Beta
1.56xvs all stocks
50-Day MA
19.61USDUpdated Sep 28, 2026200-Day MA
19.56USDUpdated Sep 28, 2026Avg 10-Day Volume
2.39MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.79MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.9000USDUpdated Sep 28, 2026Other Income / Expense
-34.15MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 5.67×, higher than 95% of its Medical Devices peers (median 0.22×)Significant
Debt-to-equity: 5.67Industry median: 0.22Industry P95: 3.06Peers compared: 60.00
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.57Profit Margin: -0.06
Significant cash reserves alongside high leverageNotable
Cash (USD): 455,996,000Total Debt (USD): 739,252,992Debt-to-Equity: 5.67
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 3.18Altman Z-Score: -0.15
Financial Health
Altman Z-Score -0.15: distress zoneCritical
Altman Z-Score: -0.15
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $1.04B, above the global median of $548.88MNotable
Revenue (USD): 1,041,417,024Global Median: 548,883,780.48
Companies that share the same coordination system — how they create, deliver, or capture value.
Sequent Scientific Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shinva Medical Instrument Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Artivion Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Boya Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Wandong Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Hongyu Wuzhou Medica Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangzhou Wondfo Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiuzhitang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lifetech Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
Amphastar Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Qingdao Eastsoft Communication Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline
Sunwoda Electronic Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline
Xianheng International Science And Technology Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline